232 related articles for article (PubMed ID: 18839776)
21. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
22. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
23. Role of ribavirin in HCV treatment response: now and in the future.
Jain MK; Zoellner C
Expert Opin Pharmacother; 2010 Mar; 11(4):673-83. PubMed ID: 20163278
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis C.
Bihl F; Negro F
Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
[TBL] [Abstract][Full Text] [Related]
25. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
Kanda T; Yokosuka O
JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
27. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
[TBL] [Abstract][Full Text] [Related]
28. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
[TBL] [Abstract][Full Text] [Related]
29. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
30. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
[TBL] [Abstract][Full Text] [Related]
31. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
32. [Attempts to treat chronic hepatitis C with HCV protease inhibitor].
Pawłowska M
Przegl Epidemiol; 2011; 65(1):35-8. PubMed ID: 21735833
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
[TBL] [Abstract][Full Text] [Related]
34. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
36. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
38. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
Ferenci P
J Antimicrob Chemother; 2004 Jan; 53(1):15-8. PubMed ID: 14645325
[TBL] [Abstract][Full Text] [Related]
39. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
Patel MR; Mullen MP; Dieterich DT
AIDS Read; 2006 Mar; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
[TBL] [Abstract][Full Text] [Related]
40. The hepatitis C revolution part 1: antiviral treatment options.
Thiagarajan P; Ryder SD
Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
